Assessing the Association Between GLP-1 Receptor Agonist Use and Diabetic Retinopathy Through the FDA Adverse Event Reporting System

Tiansheng Wang¹, Wenchao Lu^{2

3}, Huilin Tang⁴, John B Buse⁵, Til Stürmer⁶, Emily W Gower⁶

Affiliations

¹ Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC tianwang@unc.edu.
² Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital, Capital Medical University), Beijing, China.
³ Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.
⁴ Institute for Drug Evaluation, Peking University Health Science Center, Beijing, China.
⁵ Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.
⁶ Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.

Tiansheng Wang et al. Diabetes Care. 2019 Feb.

. 2019 Feb;42(2):e21-e23.

doi: 10.2337/dc18-1893. Epub 2018 Dec 7.

Tiansheng Wang¹, Wenchao Lu^{2

3}, Huilin Tang⁴, John B Buse⁵, Til Stürmer⁶, Emily W Gower⁶

¹ Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC tianwang@unc.edu.
² Peking University Ninth School of Clinical Medicine (Beijing Shijitan Hospital, Capital Medical University), Beijing, China.
³ Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, China.
⁴ Institute for Drug Evaluation, Peking University Health Science Center, Beijing, China.
⁵ Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.
⁶ Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC.

No abstract available

Figures

1. Wang T, Hong J-L, Gower EW, et al. . Incretin-based therapies and diabetic retinopathy: real-world evidence in older U.S. adults. Diabetes Care 2018;41:1998–2009 - PMC - PubMed
1. Fadini GP, Sarangdhar M, Avogaro A. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. BMJ Open Diabetes Res Care 2018;6:e000475 - PMC - PubMed
1. Fan Y, Liu K, Wang Q, Ruan Y, Ye W, Zhang Y. Exendin-4 alleviates retinal vascular leakage by protecting the blood-retinal barrier and reducing retinal vascular permeability in diabetic Goto-Kakizaki rats. Exp Eye Res 2014;127:104–116 - PubMed
1. Simó R, Hernández C. GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe? Diabetes 2017;66:1453–1460 - PubMed
1. Hernández C, Bogdanov P, Corraliza L, et al. . Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes 2016;65:172–187 - PubMed